HQYHealthcare · Health Information ServicesThe 15 Wall Street analysts covering HealthEquity, Inc. hold a median 12-month price target of $123 — +13.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores HealthEquity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (51): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HQY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.0% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | BMO Capital | Maintains | Outperform | $105 → $125 |
| 18 Sept 2026 | Barclays | Maintains | Overweight | $110 → $115 |
| 18 Sept 2026 | Barclays | Maintains | Overweight | — |
| 31 Aug 2026 | Deutsche Bank | Maintains | Buy | $135 → $142 |
| 31 Aug 2026 | Deutsche Bank | Maintains | Buy | — |
| 28 Aug 2026 | BTIG | Reiterates | Buy | $115 |
| 28 Aug 2026 | BTIG | Reiterates | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | $110 → $115 |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 3 June 2026 | RBC Capital | Reiterates | Outperform | $108 |
| 3 June 2026 | RBC Capital | Reiterates | Outperform | — |
| 1 June 2026 | Citizens | Maintains | Market Outperform | $110 → $111 |
| 1 June 2026 | Citizens | Maintains | Market Outperform | — |
| 29 May 2026 | RBC Capital | Maintains | Outperform | $100 → $108 |
| 29 May 2026 | RBC Capital | Maintains | Outperform | — |
| 22 May 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Apr 2026 | BMO Capital | Upgrade | Outperform | — |
| 19 Mar 2026 | Deutsche Bank | Maintains | Buy | — |
| 18 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 18 Mar 2026 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HQY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, HealthEquity, Inc. returned +14.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 19% of US stocks
Cheaper than 22% of US stocks
Cheaper than 17% of US stocks
Higher than 47% of US stocks
Higher than 48% of US stocks
Higher than 86% of US stocks
Higher than 86% of US stocks
Higher than 80% of US stocks
Higher than 66% of US stocks
Higher than 84% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HealthEquity, Inc. has a market value of $8.6B and an enterprise value of $9.3B.
Revenue in the twelve months to 31 July 2026: $1.4B. The latest quarter grew 7.6% year on year.
Net income over the same four quarters: $236.5M, a 17.4% net margin.
Diluted earnings per share, trailing twelve months: $2.77.
Free cash flow in the twelve months to 31 July 2026: $436.7M.
HealthEquity, Inc. spent $404.5M on share buybacks in the twelve months to 31 July 2026.
Trailing P/E: 37.4×; forward P/E: 18.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
HealthEquity, Inc. employs 2,814 people — $484K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HealthEquity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
HealthEquity announced that it will release fiscal 2027 third-quarter financial results after the market close on December 1, 2026. Management will host an investor conference call that day at 4:30 p.m. Eastern Time to review the results.
Why it matters — HQY watchers can note the date and time when the company plans to report quarterly results and discuss them with investors.
Zacks Investment Research compares Bausch + Lomb and HealthEquity as potential value options for investors interested in medical services stocks.
Why it matters — The item puts HQY in a value-investing comparison with Bausch + Lomb, relevant to readers following HealthEquity.
Zacks Investment Research says HealthEquity has solid growth attributes that could help it outperform the market. The headline frames the assessment around three reasons to view HQY as a growth stock.
Why it matters — HQY watchers may find the item relevant as a positive assessment of the company’s growth characteristics.
Zacks Investment Research’s headline presents HealthEquity (HQY) as a top long-term growth stock. The excerpt highlights Zacks Style Scores, a feature of its Zacks Premium research service, as a tool for finding stocks across value, growth, and momentum styles.
Why it matters — HQY watchers may note the article’s favorable growth framing and its reference to Zacks’ stock-screening service.
Zacks Investment Research cited HealthEquity’s strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook as sources of momentum, while noting ongoing cybersecurity risks.
Why it matters — HQY watchers may weigh the company’s growth and efficiency signals against cybersecurity concerns.
The 15 Wall Street analysts covering HealthEquity, Inc. have a median 12-month price target of $123, with estimates ranging from $108 to $142. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering HealthEquity, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HealthEquity, Inc. 95 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, HealthEquity, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +13.0% from the last close, and Ticker Nerd's factor model ranks HealthEquity, Inc. 95 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HealthEquity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HQY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $108 to $142 over the next 12 months.
HealthEquity, Inc. returned +14.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
HealthEquity, Inc. is a healthcare-fintech and benefits administration company that provides technology-enabled platforms for managing tax-advantaged health accounts and related employee benefits.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "HealthEquity Schedules Third Quarter Earnings Release Date". HealthEquity announced that it will release fiscal 2027 third-quarter financial results after the market close on December 1, 2026. Management will host an investor conference call that day at 4:30 p.m. Eastern Time to review the results.
HealthEquity, Inc. is a healthcare-fintech and benefits administration company that provides technology-enabled platforms for managing tax-advantaged health accounts and related employee benefits. HealthEquity focuses on health savings accounts, flexible spending accounts, health reimbursement arrangements, COBRA continuation services, commuter benefits, and other consumer-directed benefit programs. Its services are designed to help consumers and employers organize healthcare spending, access account information, process payments, and manage eligible investments through digital tools and support services. The company works with employers, benefits advisors, health plans, and retirement providers to administer account-based benefit programs across the United States. HealthEquity plays a key role in the consumer-directed healthcare market by combining account administration, payment capabilities, and member support in a single platform.
CEO Mr. Scott R. Cutler J.D. · 2,814 employees · United States · https://www.healthequity.com
